Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications

Blood Cells, Molecules, and Diseases

Volumn 47, Issue 1, 2011, Pages 33-40

  Farmaki, Kallistheni ^a   Tzoumari, Ioanna ^a   Pappa, Christina ^a  

^a General Hospital of Corinth   (Greece)

Author keywords

Combined chelation; Deferasirox; Deferiprone; Iron overload complications; Thalassemia major

Indexed keywords

DEFERASIROX; DEFERIPRONE; FERRITIN;

ADULT; AGRANULOCYTOSIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CYTOPENIA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE VESICLE; IRON OVERLOAD; MALE; MONOTHERAPY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY DISTRESS SYNDROME; SIDE EFFECT; SWELLING; THALASSEMIA MAJOR; THROMBOCYTOPENIA; URTICARIA;

ADMINISTRATION, ORAL; ADULT; BETA-THALASSEMIA; BLOOD GLUCOSE; BLOOD TRANSFUSION; FEMALE; GONADS; HEART; HEART FUNCTION TESTS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; THYROID GLAND; YOUNG ADULT;

EID: 79956311461     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2011.03.007     Document Type: Article

References (64)

1. Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann. N.Y. Acad. Sci. 2010, 1202:1-9.
2. Kalinowski D.S., Richardson D.R. The evolution of iron chelators, for the treatment of iron overload disease and cancer. Pharmacol. Rev. 2005 Dec, 57(4):547-583.
3. Wonke B., Wright C., Hoffbrand A.V. Combined therapy with deferiprone and desferrioxamine. Br. J. Haematol. 1998 Nov, 103(2):361-364.
4. Telfer P.T., Warburton F., Christou S., Hadjigavriel M., Sitarou M., Kolnagou A., et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica 2009 Dec, 94(12):1777-1778.
5. Tanner M.A., Galanello R., Dessi C., Smith G.C., Westwood M.A., Agus A., Pibiri M., Nair S.V., Walker J.M., Pennell D.J. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J. Cardiovasc. Magn. Reson. 2008, 10:12.
6. Tanner M.A., Galanello R., Dessi C., Smith G.C., Westwood M.A., Agus A., Roughton M., Assomull R., Nair S.V., Walker J.M., Pennell D.J. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007, 115:1876-1884.
7. Evans P., Kayyali R., Hider R.C., Eccleston J., Porter J.B. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl. Res. Aug 2010, 156(2):55-67.
8. Kattamis A., Kassou C., Berdousi H., Ladis V., Papassotiriou I., Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica Dec 2003, 88(12):1423-1425.
9. Farmaki K., Tzoumari I., Pappa C., Chouliaras G., Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br. J. Haematol. Feb 2010, 148(3):466-475.
10. Hershko C., Konijn A.M., Nick H.P., Breuer W., Cabantchik Z.I., Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood Feb 15 2001, 97(4):1115-1122.
11. Jetsrisuparb A., Komvilaisak P., Wiangnon S., Jetsrisuparb C. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2years. J. Pediatr. Hematol. Oncol. Jul 2010, 32(5):400-403.
12. Galanello R., Agus A., Campus S., Danjou F., Giardina P.J., Grady R.W. Combined iron chelation therapy. Ann. N.Y. Acad. Sci. Aug 2010, 1202:79-86.
13. Balocco M., Carrara P., Pinto V., Forni G.L. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. Am. J. Hematol. 2010 Jun, 85(6):460-461.
14. Berdoukas V., Carson S., Nord A., Dongelyan A., Gavin S., Hofstra T.C., et al. Combining two orally active iron chelators for thalassemia. Ann. Hematol. Mar 2010, 10.
15. Borgna-Pignatti C., Rugolotto S., De Stefano P., Zhao H., Cappellini M.D., Del Vecchio G.C., Romeo M.A., Forni G.L., Gamberini M.R., Ghilardi R., Piga A., Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89:1187-1193.
16. Berdoukas V., Farmaki K., Wood J.C., Coates T. Iron chelation in thalassemia: time to reconsider our comfort zones. Expert Rev. Hematol. Feb 2011, 4(1):17-26.
17. Cappellini M.D., Taher A. Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol. 2009, 122(2-3):165-173.
18. Vichinsky E. Clinical application of deferasirox: practical patient management. Am. J. Hematol. 2008, 83(5):398-402.
19. St Pierre T.G., Clark P.R., Chua-anusorn W., Fleming A.J., Jeffrey G.P., Olynyk J.K., Pootrakul P., Robins E., Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005, 105:855-861.
20. * mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005, 106:1460-1465.
21. Novartis updated full prescribing information for Exjade (deferasirox), Feb 2010 and warnings, precautions and drug interactions sections of the U.S., 2010.
22. for healthcare professionals outside US, about ferriprox, expanded indications, SPC, 2009. http://www.ferriprox.com.
23. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39(2 uppl.1):S1-S266.
24. The Criteria Committee of the New York Heart Association Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels 1994, 253-256. Little, Brown & Co, Boston, Mass. 9th ed.
25. American Diabetes Association: classification of glucose metabolism abnormalities. Diabetes Care 2005, 28(suppl):37-42.
26. Porter J.B., Shah F.T. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Hematol. Oncol. Clin. North Am. 2010 Dec, 24(6):1109-1130.
27. Kolnagou A., Yazman D., Economides C., Eracleous E., Kontoghiorghes G.J. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol. Hemoglobin 2009, 33(5):312-322.
28. Gamberini M.R., Francesconi R., Fortini M., Cavazzini L., Lari F., Scapoli C., Ballardini G., De Sanctis V., Bianchi F.B. HCV and HGV infection, iron overload and liver disease in multitransfused patients with thalassaemia and persistently normal or abnormal transaminase levels. Pediatr. Endocrinol. Rev. Dec 2004, 2(Suppl 2):259-266.
29. Singer S.T., Sweeters N., Vega O., Higa A., Vichinsky E., Cedars M. Fertility potential in thalassemia major women: current findings and future diagnostic tools. Ann. N.Y. Acad. Sci. Aug 2010, 1202:226-230.
30. Yang L.P., Keam S.J., Keating G.M. Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs 2007, 67(15):2211-2230.
31. Farmaki K., Berdoukas V. Reversal of endocrinopathies in transfusional iron overload patients-the next frontier in iron chelation. EJCMO 2010, 2(4):59-66.
32. De Sanctis V., Eleftheriou A., Malaventura C. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr. Endocrinol. Rev. 2004 Dec, 2(Suppl 2):249-255.
33. Toumba M., Sergis A., Kanaris C., Skordis N. Endocrine complications in patients with thalassaemia major. Pediatr. Endocrinol. Rev. Dec 2007, 5(2):642-648. Review.
34. Glickstein H., El R.B., Shvartsman M., Cabantchik Z.I. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005 Nov 1, 106(9):3242-3250.
35. Glickstein H., El R.B., Link G., Breuer W., Konijn A.M., Hershko C., Nick H., Cabantchik Z.I. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood Nov 1 2006, 108(9):3195-3203.
36. Porter J.B., Rafique R., Srichairatanakool S., Davis B.A., Shah F.T., Hair T., Evans P. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use. Ann. N.Y. Acad. Sci. 2005, 1054:155-168.
37. Sohn Y.S., Breuer W., Munnich A., Cabantchik Z.I. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood Feb 1 2008, 111(3):1690-1699.
38. Daar S., Pathare A., Nick H., Kriemler-Krahn U., Hmissi A., Habr D., Taher A. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur. J. Haematol. Jun 2009, 82(6):454-457.
39. Shvartsman M., Kikkeri R., Shanzer A., Ioav Z., Cabantchik I. Non-transferrin bound iron reaches mitochondria by a chelator inaccessible mechanism. Biological and clinical implications. Am. J. Physiol. Cell Physiol. 2007, 293(4):C1383-C1394.
40. Devanur L.D., Evans R.W., Evans P.J., Hider R.C. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy. Biochem. J. Jan 15 2008, 409(2):439-447.
41. Modell B., Khan M., Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000 Jun 10, 355(9220):2051-2052.
42. Anderson L.J., Westwood M.A., Prescott E., Walker J.M., Pennell D.J., Wonke B. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol. 2006, 115(1-2):106-108.
43. Anderson L.J., Westwood M.A., Holden S., Davis B., Prescott E., Wonke B., Porter J.B., Walker J.M., Pennell D.J. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br. J. Haematol. Nov 2004, 127(3):348-355.
44. Tanner M.A., Galanello R., Dessi C., Westwood M.A., Smith G.C., Nair S.V., Anderson L.J., Walker J.M., Pennell D.J. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J. Cardiovasc. Magn. Reson. 2006, 8(3):543-547.
45. Anderson L.J., Wonke B., Prescott E., Holden S., Walker J.M., Pennell D.J. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet Aug 17 2002, 360(9332):516-520.
46. Pennell D.J., Berdoukas V., Karagiorga M., Ladis V., Piga A., Aessopos A., Gotsis E.D., Tanner M.A., Smith G.C., Westwood M.A., Wonke B., Galanello R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood May 1 2006, 107(9):3738-3744. Epub 2005 Dec 13.
47. Tanner M.A., Galanello R., Dessi C., et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J. Cardiovasc. Magn. Reson. 2008, 10(1):12.
48. Pennell D.J., Porter J.B., Cappellini M.D., El-Beshlawy A., Chan L.L., Aydinok Y., Elalfy M.S., Sutcharitchan P., Li C.K., Ibrahim H., Viprakasit V., Kattamis A., Smith G., Habr D., Domokos G., Roubert B., Taher A. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood Mar 25 2010, 115(12):2364-2371.
49. Pennell D.J., Porter J.B., Cappellini M.D., Chan L.L., El-Beshlawy A., Aydinok Y., Ibrahim H., Li C.K., Viprakasit V., Elalfy M.S., Kattamis A., Smith G., Habr D., Domokos G., Roubert B., Taher A. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica 2011 Jan, 96(1):48-54.
50. Wood J.C., Glynos T., Thompson A., Giardina P., Harmatz P., Kang B.P., Paley C., Coates T.D. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Am. J. Hematol. Oct 2010, 85(10):818-819.
51. Pathare A., Taher A., Daar S. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann. Hematol. 2010 Apr, 89(4):405-409.
52. Ruffo G.B., Borsellino Z., Cuccia L., Marocco M.R., Gagliardotto F., Tarantino R. Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI. Clin. Drug Investig. 2010, 30(4):267-273.
53. Musallam K., Taher A. Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major. Haematologica February 1 2011, 96(2):e5-e6.
54. Kolnagou A., Kontoghiorghes G.J. Future challenges in the use of magnetic resonance imaging for the diagnosis of iron overload. Blood Transfus. Oct 2010, 8(4):309-310.
55. Merkel P.A., Simonson D.C., Amiel S.A., Plewe G., Sherwin R.S., Pearson H.A., Tamborlane W.V. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N. Engl. J. Med. 1988, 1998(318):809-814.
56. Jaruratanasirikul S., Chareonmuang R., Wongcharnchailert M., Laosombat V., Sangsupavanich P., Leetanaporn K. Prevalence of impaired glucose metabolism in beta-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy. Eur. J. Pediatr. Aug 2008, 167(8):873-876.
57. Farmaki K., Angelopoulos N., Anagnostopoulos G., Gotsis E., Rombopoulos G., Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br. J. Haematol. Aug 2006, 134(4):438-444.
58. Christoforidis A., Perifanis V., Athanassiou-Metaxa M. Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major. Br. J. Haematol. 2006, 135:271-272.
59. Gamberini M.R., Fortini M., De Sanctis V., Gilli G., Testa M.R. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr. Endocrinol. Rev. Dec 2004, 2(Suppl 2):285-291.
60. Noetzli L.J., Papudesi J., Coates T.D., Wood J.C. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009 Nov 5, 114(19):4021-4026.
61. Berdoukas V., Wood J. In search of the optimal iron chelation therapy for patients with thalassemia major. Haematologica January 1 2011, 96(1):5-8.
62. Cappellini M.D. Long-term efficacy and safety of deferasirox. Blood Rev. Dec 2008, 22(Suppl 2):S35-S41.
63. Scalone L., Mantovani L.G., Krol M., Rofail D., Ravera S., Bisconte M.G., Borgna-Pignatti C., Borsellino Z., Cianciulli P., Gallisai D., Prossomariti L., Stefàno I., Cappellini M.D. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr. Med. Res. Opin. Jul 2008, 24(7):1905-1917.
64. Taher A., Al Jefri A., Elalfy M.S., Al Zir K., Daar S., Rofail D., Baladi J.F., Habr D., Kriemler-Krahn U., El-Beshlawy A. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-thalassemia: results from the ESCALATOR Trial. Acta Haematol. 2010, 123(4):220-225.